2-fluoro-4-(((3S,4R)-4-hydroxy-4-(hydroxymethyl)-1-((4-(trifluoromethyl)phenyl)sulfonyl)pyrrolidin-3-yl)oxy)-benzonitrile

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-fluoro-4-(((3S,4R)-4-hydroxy-4-(hydroxymethyl)-1-((4-(trifluoromethyl)phenyl)sulfonyl)pyrrolidin-3-yl)oxy)-benzonitrile
• 英文别名: 2-fluoro-4-[(3S,4R)-4-hydroxy-4-(hydroxymethyl)-1-[4-(trifluoromethyl)phenyl]sulfonylpyrrolidin-3-yl]oxybenzonitrile
• 化学式: C₁₉H₁₆F₄N₂O₅S
• 分子量: 460.406
• InChiKey: VXWNRMAUQHKNHT-ZWKOTPCHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  31
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  119
• 氢给体数：
  2
• 氢受体数：
  11

反应信息

• 作为产物：
  描述：

  (±)-tert-butyl 3-(4-cyano-3-fluorophenoxy)-4-methylenepyrrolidine-1-carboxylate 在 盐酸 、 N-morpholine oxide 、 四氧化锇 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 二氯甲烷 、 叔丁醇 为溶剂， 反应 99.67h， 生成 2-fluoro-4-(((3S,4R)-4-hydroxy-4-(hydroxymethyl)-1-((4-(trifluoromethyl)phenyl)sulfonyl)pyrrolidin-3-yl)oxy)-benzonitrile
  参考文献：
  名称：

  Discovery of GSK3527497: A Candidate for the Inhibition of Transient Receptor Potential Vanilloid-4 (TRPV4)

  摘要：

  GSK3527497, a preclinical candidate for the inhibition of TRPV4, was identified starting from the previously reported pyrrolidine sulfonamide TRPV4 inhibitors 1 and 2. Optimization of projected human dose was accomplished by specifically focusing on in vivo pharmacokinetic parameters CLu, Vdss(u), and MRT. We highlight the use of conformational changes as a novel approach to modulate Vdss(u) and present results that suggest that molecular-shape-dependent binding to tissue components governs Vdss(u) in addition to bulk physicochemical properties. Optimization of CLu within the series was guided by in vitro metabolite identification, and the poor FaSSIF solubility imparted by the crystalline properties of the pyrrolidine diol scaffold was improved by the introduction of a charged moiety to enable excellent exposure from high crystalline doses. GSK3527497 is a preclinical candidate suitable for oral and iv administration that is projected to inhibit TRPV4 effectively in patients from a low daily clinical dose.

  DOI：

  10.1021/acs.jmedchem.9b01247

文献信息

• TRPV4 antagonists
  申请人：GlaxoSmithKline Intellectual Property (No. 2) Limited

  公开号：US10588891B2

  公开（公告）日：2020-03-17

  The present invention relates to pyrrolidine sulfonamide analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.

  本发明涉及吡咯烷磺酰胺类似物、含有它们的药物组合物及其作为 TRPV4 拮抗剂的用途。
• TRPV4 ANTAGONISTS
  申请人：GlaxoSmithKline Intellectual Property (No. 2) Limited

  公开号：EP3515887B1

  公开（公告）日：2021-07-07